Trials / Terminated
TerminatedNCT01745224
Revlite Laser System Compared to the Candela Alex TriVantage System Refractory Mixed Type Melasma
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Cynosure, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This proof of concept study will be conducted to assess the aesthetic improvement in refractory mixed type melasma in subjects treated with two FDA 510K approved devices: Q Switched Nd: YAG Laser vs. Alex TriVantage
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Revlite Q switched Nd:YAG | Revlite Q switched Nd:YAG 1064nm |
| DEVICE | Trivantage Q switched Nd: YAG | Trivantage Q switched Nd: YAG 1064nm |
Timeline
- Start date
- 2012-07-01
- Primary completion
- 2013-07-01
- Completion
- 2013-07-01
- First posted
- 2012-12-10
- Last updated
- 2020-12-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01745224. Inclusion in this directory is not an endorsement.